[2021] Diabetic Ketoacidosis Treatment Market Trends Analysis, Growth Insights, Size Estimation, Key Companies Profile, Share Analysis and Global Market Statistics By 2026

SEATTLE, April 14, 2021, (PHARMIWEB) — Overview:

Diabetic ketoacidosis (DKA) is a severe diabetic complication. When the body does not produce enough insulin, the disease progresses. Insulin aids glucose entry into cells and tissues; without it, the body breaks down fats for food, resulting in the production of acid in the bloodstream known as ketones. If the process persists for a prolonged period of time, a complete chemical equilibrium imbalance occurs, posing a life-threatening condition.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4255

Covid-19 Impact:

According to the Lancet, diabetes is linked to a higher risk of COVID-19 infection and people with diabetes who are infected with COVID-19 need a higher insulin dose to prevent serious complications like diabetic ketoacidosis. Furthermore, healthcare professionals are confronted with a number of problems when it comes to treating diabetic ketoacidosis patients in intensive care units. This is due to the growing demand on ICUs to treat COVID-19 critical cases.

Drivers:

The global diabetic ketoacidosis treatment market is driven by high incidence of diabetes Diabetic ketoacidosis is widespread in adults with type 1 diabetes. according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Furthermore, increasing awareness regarding diabetic ketoacidosis is also expected to fuel growth of global diabetic ketoacidosis treatment market. For instance, in April 2020, Diabetes UK, a healthcare and research association, stated that the National Health Services should be kept open for emergency conditions such diabetic ketoacidosis as they may lead to life threating situation

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4255

Restraints:

Insulin given intravenously allows sugar to reach cells, causing blood sugar levels to drop and hypoglycemia to develop. However, rapidly adjusting blood sugar levels with the aid of fluids and insulin can cause brain swelling. Fluid and insulin administration can cause a drop in potassium levels in the blood, impairing heart, muscle, and nervous system functions. These factors are expected to hinder growth of the global diabetic ketoacidosis treatment market.

Market Taxonomy:

Global diabetic ketoacidosis treatment market is segmented into:

• By Treatment Type:
  • Electrolyte Replacement
  • Fluid Replacement
  • Insulin Therapy
• By Application:
  • Adults
  • Pediatric
• By End User:
  • Hospital
  • Ambulatory Care Centre
  • Speciality Clinics
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Regional Analysis:

High incidence of diabetes is expected to propel growth of the diabetic ketoacidosis treatment market in North America. According to International Diabetes Federation’s IDF Diabetes Atlas 2019 Edition, the numbers of adults with diabetes in the U.S. was 31.0 million.

The market in Europe is also driven by high incidence of diabetes in the region. For instance, according to the International Diabetes Federation, incidence rate of diabetes in Europe was 77% up until 2019.

In Europe, intravenous insulin and electrolyte fluids are highly used treatments for diabetic ketoacidosis. Basal insulin with daily insulin fusion is well successful and a key therapy for diabetic ketoacidosis, according to the European Journal of Internal Medicine in 2018.

Market Trends

The market is witnessing several M&A activities. For instance, in 2019, Medtronic, an Irish medical device company, merged with Nova Nordisk, a Danish pharmaceutical company, to develop diabetes and diabetic ketoacidosis solutions by combining insulin dosage data from future Novo Nordisk and Medtronic Continuous Glucose Monitoring (CGM) devices with data from smart insulin pens.

Major players involved in the global diabetic ketoacidosis treatment market are focused on adopting various strategies to enhance their market share. For example, in June 2020, Lexicon Pharmaceutical Inc. announced the use of Zynquista (sotagliflozin) to balance the risk of diabetes ketoacidosis in adults with type-1 diabetes.

Major players involved in the global diabetic ketoacidosis treatment market are also focused on launching new products to enhance their market share. For instance, in August 2020, Eli Lilly and Company introduced two non-branded insulin products, Humalog mix 75/25 kwikpen and Humalog Junior kwikpen.

Competitive Analysis:

Major players involved in the global diabetic ketoacidosis treatment market are Novo Nordisk A/S, Sanofi S.A, Biocon Limited, Tonghua Dongbao Pharmaceutical Co., Ltd, Oramed Pharmaceuticals Inc., Merck & Co., Inc., Pfizer Inc., Wockhardt Ltd, Eli Lilly and Company, GlaxoSmithKline plc, and Bristol Myers Squibb.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837